Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560137 | 1.00 | CACNA1B (0.50) | CACNA1BCTSKCTSSCTSLCTSB | |
| SCHEMBL8256601 | 1.00 | CACNA1B (0.50) | CACNA1BCTSKCTSSCTSLCTSB | |
| SCHEMBL3579962 | 0.90 | CACNA1B (0.51) | CACNA1BCTSKCTSSCTSLCTSB | |
| SCHEMBL3579958 | 0.90 | CACNA1B (0.51) | CACNA1BCTSKCTSSCTSLCTSB | |
| SCHEMBL3579959 | 0.90 | CACNA1B (0.51) | CACNA1BCTSKCTSSCTSLCTSB | |
| SCHEMBL16330581 | 0.85 | CACNA1B (0.52) | CACNA1BCTSKCTSSSMN1; SMN2GAA | |
| SCHEMBL28628007 | 0.85 | CACNA1B (0.52) | CACNA1BCTSKCTSSGAAHDAC4 | |
| SCHEMBL16469897 | 0.85 | CACNA1B (0.52) | CACNA1BCTSKCTSSGAAHDAC4 | |
| SCHEMBL3576555 | 0.84 | CAPN1 (0.52) | CACNA1BCTSKCTSSCTSLCTSB | |
| SCHEMBL3576552 | 0.84 | CAPN1 (0.52) | CACNA1BCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421844-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Ltd. (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LD. (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122294-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | IKBKE, IKBKB, NFKBIA | CACNA1B 2996/4885CTSK 4212/4885CTSS 4785/4885 |
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | CACNA1B 4797/4885CTSK 439/4885CTSS 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.